Ionis Pharmaceuticals
Search results
Some see slow and steady scientific progress. We see a revolution. Sarepta is a global biotechnology company on an urgent mission: engineer precision genetic medicine to reclaim futures otherwise impacted or cut short by rare diseases.
Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We’re ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world’s largest gene ...
Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors. 09/05/2024. Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year.
We’re looking for people who see unlimited potential in themselves, backed by an unwavering commitment to patients. Learn more about careers at Sarepta.
The Investor Relations website contains information about Sarepta Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Sarepta is pursuing the development of precision genetic medicine at the forefront of biotechnology for rare diseases: gene therapy, RNA-targeted exon skipping, and gene editing.
Jun 27, 2024 · Sarepta’s industry leading pipeline is comprised of over 40 programs in various stages of development across 3 technologies, RNA, gene therapy and gene editing, and multiple therapeutic areas including neuromuscular, CNS and cardiology.
Nov 28, 2022 · “We are delighted to announce that the FDA has accepted Sarepta’s BLA for SRP-9001 for filing and priority review,” said Doug Ingram, president and chief executive officer, Sarepta Therapeutics.
Feb 16, 2024 · CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Feb. 16, 2024-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted and filed the Company's efficacy supplement to the Biologics License Application (BLA) for ELEVIDYS (delandistrogene ...
Jun 20, 2024 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 20, 2024-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced U.S. Food and Drug Administration (FDA) approval of an expansion to the labeled indication for ELEVIDYS (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne ...
